CYRAMZA, in combination with erlotinib, now approved for the treatment of people with untreated metastatic non-small cell lung cancer (NSCLC) with certain activating EGFR mutations, based on the positive global Phase 3 RELAY study
CYRAMZA regimen reduced the risk of disease progression or death by 41 percent compared to erlotinib in this patient population
PR Newswire
INDIANAPOLIS, May 29, 2020